Basic biology of gliomas

Research output: Contribution to journalArticle

Abstract

Gliomas are a group of primary brain neoplasms classified mainly on the basis of their morphological resemblance to glial cells. Their most malignant form, grade IV glioma or glioblastoma multiforme, continues to remain lethal, partly due to a pronounced intratumoral heterogeneity which prevents effective therapeutic targeting. The heterogeneity seen in glioblastomas ranges from multiple genetic and epigenetic alterations to a cellular diversity that has recently been traced to the existence of tumor stem cells.Glioma stem cells, like other types of cancer stem cells, have the ability to self-renew and differentiate into multiple tissue-specific lineages. They can therefore maintain and propagate the tumor by continuously giving rise to a variety of malignant offspring and also initiate tumor recurrence from a very small number of cells. Furthermore, they are also considered to be the cells most likely to survive even multi-modality treatments, due to characteristics such as slow cycling or quiescence, high drug efflux capacity and strong antioxidant and immune defense systems.With the addition of each new research finding, the concept of glioma stem cell itself continues to evolve. However, many aspects of glioma stem cell biology are still insufficiently understood. It is not known which cells they originate from, what their relationship to normal tissue stem cells is and what mechanisms or events underlie their malignant transformation. Furthermore, whether the answers to these questions are the same for all glioma stem cells is also a matter that requires further investigation.This review focuses on our current understanding of glioma stem cells, the signaling pathways behind their pathogenic features and their role in glioma biology. We also discuss possible answers to the questions mentioned above, in the context of knowledge obtained from the study of tumor stem cells of several other types of malignancies. Finally, we review the importance of glioma stem cells in treatment resistance in glioblastoma and the implications of stem cell-specific targeting strategies.

Original languageEnglish
Pages (from-to)541-546
Number of pages6
JournalJapanese Journal of Neurosurgery
Volume23
Issue number7
Publication statusPublished - 2014

Fingerprint

Glioma
Stem Cells
Neoplastic Stem Cells
Glioblastoma
Neoplasms
Epigenomics
Brain Neoplasms
Neuroglia
Cell Biology
Immune System
Therapeutics
Cell Count
Antioxidants
Recurrence
Research
Pharmaceutical Preparations

Keywords

  • Anti-oncogene
  • Cancer stem cell
  • Glioma
  • ICSC
  • Oncogene

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Basic biology of gliomas. / Saya, Hideyuki; Shibao, Shunsuke; Sampetrean, Oltea.

In: Japanese Journal of Neurosurgery, Vol. 23, No. 7, 2014, p. 541-546.

Research output: Contribution to journalArticle

Saya, Hideyuki ; Shibao, Shunsuke ; Sampetrean, Oltea. / Basic biology of gliomas. In: Japanese Journal of Neurosurgery. 2014 ; Vol. 23, No. 7. pp. 541-546.
@article{1abcc0877e1a48cda57dcc18ef8ab825,
title = "Basic biology of gliomas",
abstract = "Gliomas are a group of primary brain neoplasms classified mainly on the basis of their morphological resemblance to glial cells. Their most malignant form, grade IV glioma or glioblastoma multiforme, continues to remain lethal, partly due to a pronounced intratumoral heterogeneity which prevents effective therapeutic targeting. The heterogeneity seen in glioblastomas ranges from multiple genetic and epigenetic alterations to a cellular diversity that has recently been traced to the existence of tumor stem cells.Glioma stem cells, like other types of cancer stem cells, have the ability to self-renew and differentiate into multiple tissue-specific lineages. They can therefore maintain and propagate the tumor by continuously giving rise to a variety of malignant offspring and also initiate tumor recurrence from a very small number of cells. Furthermore, they are also considered to be the cells most likely to survive even multi-modality treatments, due to characteristics such as slow cycling or quiescence, high drug efflux capacity and strong antioxidant and immune defense systems.With the addition of each new research finding, the concept of glioma stem cell itself continues to evolve. However, many aspects of glioma stem cell biology are still insufficiently understood. It is not known which cells they originate from, what their relationship to normal tissue stem cells is and what mechanisms or events underlie their malignant transformation. Furthermore, whether the answers to these questions are the same for all glioma stem cells is also a matter that requires further investigation.This review focuses on our current understanding of glioma stem cells, the signaling pathways behind their pathogenic features and their role in glioma biology. We also discuss possible answers to the questions mentioned above, in the context of knowledge obtained from the study of tumor stem cells of several other types of malignancies. Finally, we review the importance of glioma stem cells in treatment resistance in glioblastoma and the implications of stem cell-specific targeting strategies.",
keywords = "Anti-oncogene, Cancer stem cell, Glioma, ICSC, Oncogene",
author = "Hideyuki Saya and Shunsuke Shibao and Oltea Sampetrean",
year = "2014",
language = "English",
volume = "23",
pages = "541--546",
journal = "Japanese Journal of Neurosurgery",
issn = "0917-950X",
publisher = "Japanese Congress of Neurological Surgeons",
number = "7",

}

TY - JOUR

T1 - Basic biology of gliomas

AU - Saya, Hideyuki

AU - Shibao, Shunsuke

AU - Sampetrean, Oltea

PY - 2014

Y1 - 2014

N2 - Gliomas are a group of primary brain neoplasms classified mainly on the basis of their morphological resemblance to glial cells. Their most malignant form, grade IV glioma or glioblastoma multiforme, continues to remain lethal, partly due to a pronounced intratumoral heterogeneity which prevents effective therapeutic targeting. The heterogeneity seen in glioblastomas ranges from multiple genetic and epigenetic alterations to a cellular diversity that has recently been traced to the existence of tumor stem cells.Glioma stem cells, like other types of cancer stem cells, have the ability to self-renew and differentiate into multiple tissue-specific lineages. They can therefore maintain and propagate the tumor by continuously giving rise to a variety of malignant offspring and also initiate tumor recurrence from a very small number of cells. Furthermore, they are also considered to be the cells most likely to survive even multi-modality treatments, due to characteristics such as slow cycling or quiescence, high drug efflux capacity and strong antioxidant and immune defense systems.With the addition of each new research finding, the concept of glioma stem cell itself continues to evolve. However, many aspects of glioma stem cell biology are still insufficiently understood. It is not known which cells they originate from, what their relationship to normal tissue stem cells is and what mechanisms or events underlie their malignant transformation. Furthermore, whether the answers to these questions are the same for all glioma stem cells is also a matter that requires further investigation.This review focuses on our current understanding of glioma stem cells, the signaling pathways behind their pathogenic features and their role in glioma biology. We also discuss possible answers to the questions mentioned above, in the context of knowledge obtained from the study of tumor stem cells of several other types of malignancies. Finally, we review the importance of glioma stem cells in treatment resistance in glioblastoma and the implications of stem cell-specific targeting strategies.

AB - Gliomas are a group of primary brain neoplasms classified mainly on the basis of their morphological resemblance to glial cells. Their most malignant form, grade IV glioma or glioblastoma multiforme, continues to remain lethal, partly due to a pronounced intratumoral heterogeneity which prevents effective therapeutic targeting. The heterogeneity seen in glioblastomas ranges from multiple genetic and epigenetic alterations to a cellular diversity that has recently been traced to the existence of tumor stem cells.Glioma stem cells, like other types of cancer stem cells, have the ability to self-renew and differentiate into multiple tissue-specific lineages. They can therefore maintain and propagate the tumor by continuously giving rise to a variety of malignant offspring and also initiate tumor recurrence from a very small number of cells. Furthermore, they are also considered to be the cells most likely to survive even multi-modality treatments, due to characteristics such as slow cycling or quiescence, high drug efflux capacity and strong antioxidant and immune defense systems.With the addition of each new research finding, the concept of glioma stem cell itself continues to evolve. However, many aspects of glioma stem cell biology are still insufficiently understood. It is not known which cells they originate from, what their relationship to normal tissue stem cells is and what mechanisms or events underlie their malignant transformation. Furthermore, whether the answers to these questions are the same for all glioma stem cells is also a matter that requires further investigation.This review focuses on our current understanding of glioma stem cells, the signaling pathways behind their pathogenic features and their role in glioma biology. We also discuss possible answers to the questions mentioned above, in the context of knowledge obtained from the study of tumor stem cells of several other types of malignancies. Finally, we review the importance of glioma stem cells in treatment resistance in glioblastoma and the implications of stem cell-specific targeting strategies.

KW - Anti-oncogene

KW - Cancer stem cell

KW - Glioma

KW - ICSC

KW - Oncogene

UR - http://www.scopus.com/inward/record.url?scp=84923914203&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923914203&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84923914203

VL - 23

SP - 541

EP - 546

JO - Japanese Journal of Neurosurgery

JF - Japanese Journal of Neurosurgery

SN - 0917-950X

IS - 7

ER -